- Bradycardia in ACLS:
- IV 0.5-1mg every 3-5min PRN
- IV 0.5-1mg every 3-5min PRN
- Anesthesia adjunct:
- SC/IM/IV 0.5-1mg every 4-6hours PRN
- Max: 3 mg/total dose
- Info: give 1st dose 30-60min pre-op
- 03-0.04mg/kg/max total dose for patients with CAD
- Neuromuscular blockade reversal adjunct:
- IV 0.6-1.2mg for each 0.5-2.5mg neostigmine or 10-20mg pyridostigmine dose
- IV 0.6-1.2mg for each 0.5-2.5mg neostigmine or 10-20mg pyridostigmine dose
- Organophosphate nerve agent poisoning:
- Adults: Initially IM 2-4mg x1 for mild/moderate symptoms; IM 6mg x1 for severe symptoms
- Continue atropinization until muscarinic symptoms gone
- For frail/elderly patients start IM 1mg *1 for mild/moderate symptoms, IM 2-4 mg *1 for severe symptoms
- Adults: Initially IM 2-4mg x1 for mild/moderate symptoms; IM 6mg x1 for severe symptoms
-
- <2 years old: IM 0.05mg/kg/dose every 5-10min PRN
- IM 0.1mg/kg/dose for severe symptoms
- IM 0.1mg/kg/dose for severe symptoms
- <2 years old: IM 0.05mg/kg/dose every 5-10min PRN
-
- 2-10 year old: IM 1mg every 5-10min PRN
- IM 2mg *1 for severe symptoms
- IM 2mg *1 for severe symptoms
- 2-10 year old: IM 1mg every 5-10min PRN
-
- >10 year old: IM 2mg every 5-10min PRN
- IM 4mg *1 for severe symptoms
- IM 4mg *1 for severe symptoms
- >10 year old: IM 2mg every 5-10min PRN
- Organophosphate or carbamate insecticide poisoning:
- Adults: IV 1-3mg x1, then may double dose every 3-5min PRN
- May give 10-20% loading dose/hour IV infusion once patient is stabilized
- Continue atropinization until muscarinic symptoms gone
- Adults: IV 1-3mg x1, then may double dose every 3-5min PRN
-
- Paeds: Initially IV 0.02mg/kg/dose x1, then may double dose every 3-5min PRN
Injection: 0.6mg/mL
Give into large vein or IV tubing over 1-2 min
It competitively inhibits action of acetylcholine on autonomic effectors innervated by postganglionic nerves. It reverses muscarinic effects of cholinergic poisoning caused by agents with cholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at the muscarinic receptors.
It blocks action of acetylcholine at parasympathetic sites in secretory glands, and CNS. It inhibits salivation, tracheobronchial secretions, bradycardia and hypotension
- Xerostomia
- Blurred vision
- Photophobia
- Tachycardia
- Constipation
- Difficulty urinating
- Xeroderma
- Mydriasis
- Confusion
- Headache
- Dizziness
- Flushing
- Urinary retention
- Abdominal distension
- Nausea & vomiting
- Heat intolerance
- Impaired body temperature regulation
- Restlessness
- Tremor
- Fatigue
- Injection site pain
- Rash
- Delirium
- Impotence
- Hypersensitivity to class/components
- Potassium salts
Drug Status
Availability | Prescription only |
Pregnancy | Use with caution |
Breastfeeding | Use with caution |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Atrop | 1% w/v | Eye Drops | 5mL | Dawa Ltd | Dawa Ltd |
Atropine | 1% w/v | Injection | 10’s | Dawa Ltd | Dawa Ltd |
Atropine | 0.6mg/mL | Injection | 10’s | Laborate India | Harley’s Ltd |
Atro | 1mg/mL | Injection | 10’s | Zawadi Healthcare | Zawadi Healthcare |
Atrop | 1% w/v | Eye Drops | 5mL | Aurolab | Aurolab |
Atropine Sulphate | 0.1mg/mL | Pre-filled Syringe | 5mL*10’s | Laboratoire Renaudin | Nairobi Pharma |
Atropine Sulphate | 0.2mg/mL | Pre-filled Syringe | 5mL*10’s | Laboratoire Renaudin | Nairobi Pharma |